Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.
You may also be interested in...
If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.